ALK4290 (AKST4290) 是一种有效的，具有口服活性的 CCR3 抑制剂，对 hCCR3 的 Ki 值为 3.2 nM，详细信息请参考专利文献 US20130261153A1 中的化合物 Example 2。ALK4290 可用于研究新生血管性年龄相关性黄斑变性和帕金森症。
货号:ajcx34500
CAS:1251528-23-0
分子式:C27H34ClN5O3
分子量：512.04
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3].

[1]. NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.
[2]. Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259.
[3]. Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic